NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
Clinical Trials
127 trialsNCT05837455 2026-04-13
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Washington University School of Medicine
Phase 2 Recruiting
NCT04886531 2026-04-08
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04569747 2026-04-02
ADEPT
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05524584 2026-03-11
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
Phase 2 Recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT05896566 2026-02-24
PREcoopERA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03624244 2026-02-17
BFR-ESS
Centre Leon Berard
Phase 2 Recruiting
NCT06001762 2026-01-16
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT02942355 2026-01-07
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05150652 2026-01-07
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
University of Kentucky
Phase 2 Active not recruiting
NCT05501704 2026-01-07
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04553770 2025-11-10
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT04272801 2025-10-22
POWER
University of Virginia
Phase 2 Active not recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT06086704 2025-10-01
Study of 18F-FFNP Breast PET/MRI
University of Wisconsin, Madison
Phase 2 Recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT05549505 2025-08-29
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Arvinas Inc.
Phase 2 Completed
NCT07101159 2025-08-03
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT02476786 2025-07-28
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Washington University School of Medicine
Phase 2 Recruiting
NCT03909152 2025-07-28
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05472792 2025-05-23
CAMERAN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT05190094 2025-05-07
ICRG0201
International Cancer Research Group, United Arab Emirates
Phase 2 Recruiting
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT02206984 2025-03-11
Endocrine Response in Women With Invasive Lobular Breast Cancer
University of Pittsburgh
Phase 2 Completed
NCT03944434 2025-02-26
FACILE
Fondazione Sandro Pitigliani
Phase 2 Active not recruiting
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04719273 2025-01-08
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Thomas Jefferson University
Phase 2 Active not recruiting
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04985266 2024-12-05
TRAK-ER
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT04714619 2023-12-19
CAILA
MedSIR
Phase 2 Terminated
NCT02585388 2023-09-06
CHEOPS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed